DE3485299D1 - Nachweis von antigen aktiven aminosaeurensequenzen. - Google Patents

Nachweis von antigen aktiven aminosaeurensequenzen.

Info

Publication number
DE3485299D1
DE3485299D1 DE8484900955T DE3485299T DE3485299D1 DE 3485299 D1 DE3485299 D1 DE 3485299D1 DE 8484900955 T DE8484900955 T DE 8484900955T DE 3485299 T DE3485299 T DE 3485299T DE 3485299 D1 DE3485299 D1 DE 3485299D1
Authority
DE
Germany
Prior art keywords
amino acid
detection
acid sequences
antigent
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8484900955T
Other languages
English (en)
Inventor
Mario Geysen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiron Mimotopes Pty Ltd
Original Assignee
Commonwealth Serum Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3770023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3485299(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Commonwealth Serum Laboratories filed Critical Commonwealth Serum Laboratories
Application granted granted Critical
Publication of DE3485299D1 publication Critical patent/DE3485299D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
DE8484900955T 1983-03-08 1984-03-08 Nachweis von antigen aktiven aminosaeurensequenzen. Expired - Lifetime DE3485299D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPF834883 1983-03-08
PCT/AU1984/000039 WO1984003564A1 (en) 1983-03-08 1984-03-08 Method of determining antigenically active amino acid sequences

Publications (1)

Publication Number Publication Date
DE3485299D1 true DE3485299D1 (de) 1992-01-09

Family

ID=3770023

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484900955T Expired - Lifetime DE3485299D1 (de) 1983-03-08 1984-03-08 Nachweis von antigen aktiven aminosaeurensequenzen.

Country Status (10)

Country Link
US (1) US5595915A (de)
EP (1) EP0138855B2 (de)
JP (1) JPH063445B2 (de)
AT (1) ATE69890T1 (de)
CA (1) CA1220420A (de)
DE (1) DE3485299D1 (de)
DK (1) DK164529C (de)
NO (1) NO166466C (de)
NZ (1) NZ207394A (de)
WO (1) WO1984003564A1 (de)

Families Citing this family (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
AU579148B2 (en) * 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5998578A (en) * 1984-05-18 1999-12-07 New England Medical Center Hospitals, Inc. Biologically active fragments of IL-1β
JPH07119760B2 (ja) * 1984-07-24 1995-12-20 コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション ミモトープを検出または決定する方法
AU592311B2 (en) * 1984-07-24 1990-01-11 Coselco Mimotopes Pty Ltd Method for determining mimotopes
US4762706A (en) * 1984-10-17 1988-08-09 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
AU592560B2 (en) * 1985-04-22 1990-01-18 Coselco Mimotopes Pty Ltd Improved method for determining mimotopes
IL79881A (en) * 1985-08-28 1995-12-08 Pieczenik George Populations of random coding series of oligonucleotides and peptides
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US5075211A (en) * 1986-03-26 1991-12-24 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
IE64356B1 (en) * 1986-07-28 1995-07-26 Bioscience Int Inc Diagnosis severity prediction and monitoring of disease by immunoassay of free activation peptides of pancreatic zymogens
GB8709274D0 (en) * 1987-04-16 1987-05-20 Wellcome Found Peptides
US4981782A (en) * 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5780038A (en) * 1987-11-16 1998-07-14 Roche Diagnostic Systems, Inc. HIV-2 envelope polypeptides
US5200320A (en) * 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) * 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) * 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US7811751B2 (en) 1988-05-03 2010-10-12 Oxford Gene Technology Limited Analysing polynucleotide sequences
FR2631451A1 (fr) * 1988-05-13 1989-11-17 Inst Nat Sante Rech Med Procede de caracterisation de l'epitope intervenant dans une reaction antigene anticorps, kit ou necessaire pour la mise en oeuvre du procede
US5003043A (en) * 1988-05-25 1991-03-26 Triton Biosciences Inc. Peptides representing epitopic sites for the major HTLV-I envelope protein, antibodies thereto, and uses thereof
DE3911794A1 (de) * 1989-04-11 1990-10-18 Thomae Gmbh Dr K Monoklonale antikoerper gegen rekombinaten humanen gewebeplasminogenaktivator mit definierter epitopspezifitaet, deren herstellung und deren verwendung
US5243030A (en) * 1989-05-24 1993-09-07 Sri International Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5286789A (en) * 1989-05-26 1994-02-15 Applied Immune Sciences, Inc. Solid phase multiple peptide synthesis
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
WO1991002078A1 (en) 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
DE3935572A1 (de) * 1989-10-25 1991-05-02 Biotechnolog Forschung Gmbh Verfahren zur peptidsynthese und traeger dafuer
FI910245A (fi) * 1990-01-24 1991-07-25 United Biomedical Inc Syntetiska peptidkompositioner med immunoreaktivitet mot htlv-antikroppar.
US5366862A (en) * 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
EP0445801A3 (en) * 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US6197529B1 (en) 1990-11-21 2001-03-06 Torrey Pines Institute For Molecular Studies Linear substituted oligoalkyleneimine libraries
WO1992009300A1 (en) * 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
EP1046421B8 (de) * 1990-12-06 2006-01-11 Affymetrix, Inc. (a Delaware Corporation) Verfahren und Reagenzien für immobilisierten Polymersynthese in sehr grossem Masstab
EP0600036A1 (de) * 1991-08-21 1994-06-08 Receptor Laboratories, Inc. Verfahren zur erzeugung und sortierung von nuetzlichen peptiden
WO1993004204A1 (en) * 1991-08-23 1993-03-04 Isis Pharmaceuticals, Inc. Synthetic unrandomization of oligomer fragments
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
AU669489B2 (en) * 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5811246A (en) * 1991-12-17 1998-09-22 The Research Foundation Of State University Of New York Process for immobilization onto the surfaces of ELISA plates of a compound carrier complex and for immunization
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
EP0582450A3 (de) * 1992-08-03 1994-11-23 Rohto Pharma Antikörper gegen Oxytocin-Rezeptor und deren Herstellung.
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US6448379B1 (en) * 1993-09-14 2002-09-10 Chiron Corporation IL8 inhibitors
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5559023A (en) * 1994-02-10 1996-09-24 Cancer Institute Tumor suppressor gene
US5834245A (en) * 1994-07-29 1998-11-10 Cancer Institute PRLTS proteins and DNA's encoding the same
JP2002503943A (ja) 1994-08-12 2002-02-05 ミリアド・ジェネティックス・インコーポレイテッド １７ｑ−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性
WO1996005307A2 (en) 1994-08-12 1996-02-22 Myriad Genetics, Inc. 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6121489A (en) * 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
DE69736820T2 (de) 1996-03-07 2007-08-09 Eisai Co., Ltd. Mäuse Adhesions Molekül Occludin
JP3894381B2 (ja) * 1996-04-10 2007-03-22 株式会社ペプチド研究所 抗Ｇｌｕ▲１７▼−オステオカルシン抗体
AU4055697A (en) 1996-08-16 1998-03-06 Schering Corporation Mammalian cell surface antigens; related reagents
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
ATE552341T1 (de) 1996-10-01 2012-04-15 Geron Corp Katalytische untereinheit der menschlichen telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US5919638A (en) * 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20050202499A1 (en) 1996-10-31 2005-09-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
EP1114864B9 (de) 1996-12-13 2013-05-08 Schering Corporation Oberflächenantigene aus Säugern
JP3618497B2 (ja) * 1996-12-27 2005-02-09 富士通株式会社 タンパク質の抗原決定基予測方法及びシステム
US5981201A (en) 1997-01-08 1999-11-09 Beth Israel Deaconess Medical Center Methods of detection and treatment of breast cancer
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
US6262242B1 (en) 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AR014891A1 (es) 1997-07-09 2001-04-11 Schering Corp Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
CA2382506A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Novel polypeptides and nucleic acids encoding pro293 which are useful for treating disorders of the pancreas
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2311640A1 (en) 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
US6780609B1 (en) 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
US6579682B1 (en) 1998-03-10 2003-06-17 The Regents Of University Of California Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
DK1076703T4 (da) 1998-05-15 2011-03-28 Genentech Inc Terapeutiske anvendelser af IL-17-homologe polypeptider
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6322976B1 (en) 1998-05-28 2001-11-27 Medical Research Council Compositions and methods of disease diagnosis and therapy
ATE423314T1 (de) 1998-06-24 2009-03-15 Illumina Inc Dekodierung von matrixartig-angeordneten sensoren durch mikropartikel
WO2000000610A2 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7173115B2 (en) 2000-01-13 2007-02-06 Genentech, Inc. Stra6 polypeptides
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
EP0997476A3 (de) 1998-09-25 2000-07-19 Schering-Plough Antikörper gegen ein Antigen auf Langerhans Zellen in Säugetieren und deren Verwendungen
AU2002318972B8 (en) 2001-07-18 2007-08-09 Bionomics Limited Mutations in ion channels
EP1484338B1 (de) 1998-12-22 2007-02-07 Genentech, Inc. Verfahren und Zusammensetzung zur Hemmung des neoplastischen Zellwachstums
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US7612020B2 (en) * 1998-12-28 2009-11-03 Illumina, Inc. Composite arrays utilizing microspheres with a hybridization chamber
ATE420894T1 (de) 1999-03-11 2009-01-15 Schering Corp Cytokine aus säugetieren, verwandte reagenzien und verfahren
JP4174183B2 (ja) 1999-03-23 2008-10-29 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2002544522A (ja) * 1999-05-14 2002-12-24 マクギル ユニバーシティー タンパク質間相互作用並びに相互作用するタンパク質および相互作用部位のアミノ酸配列を同定する方法
EP1684077A1 (de) * 1999-05-14 2006-07-26 McGill University Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine
AU5152700A (en) 1999-06-15 2001-01-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SI1200592T1 (sl) 1999-07-30 2010-01-29 Schering Corp Sesalski citokini; sorodni reagenti
US6632628B1 (en) 1999-08-20 2003-10-14 Board Of Regents, The University Of Texas System Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression
EP1905832A3 (de) 1999-09-09 2009-09-09 Schering Corporation Säuger Interleukin-12 P40 und Interleukin B30, Antikörper, Verwendungen in pharmazeutischen Zusammenstellungen
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
NZ531141A (en) 1999-10-20 2005-07-29 Genentech Inc Modulation of T cell differentiation for the treatment of T helper cell mediated diseases
DE19953775A1 (de) 1999-11-09 2001-05-10 Bayer Ag Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
EP1690872A3 (de) 1999-12-01 2006-08-23 Genentech, Inc. Zusammensetzung und Verfahren zur Diagnose eines Tumors
EP1897947B1 (de) 1999-12-23 2012-01-18 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
EP1125905A1 (de) * 2000-02-16 2001-08-22 Pepscan Systems B.V. Synthese von Segmenten
EP2295070B1 (de) 2000-04-12 2015-08-12 Vib Vzw Verwendung von VEGF und Homologen zur Behandlung von neurologischen Störungen
AU2001259063A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
WO2001085796A2 (en) 2000-05-12 2001-11-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
US6573370B1 (en) 2000-05-19 2003-06-03 Regents Of The University Of Michigan PON3 and uses thereof
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
WO2001095928A2 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion
AU2001266975A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. G-protein coupled receptors
EP2075253A1 (de) 2000-06-23 2009-07-01 Genentech, Inc. Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
EP2014298A3 (de) 2000-08-24 2009-10-07 Genentech, Inc. Interleukin-22-Polypeptide, Nukleinsäuren zu deren Codierung und Verfahren zur Behandlung von Bauchspeicheldrüsenerkrankungen
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
WO2002024325A2 (en) 2000-09-25 2002-03-28 Picoliter, Inc. Acoustic ejection of fluids from a plurality of reservoirs
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
EP1197755A1 (de) 2000-10-11 2002-04-17 Pepscan Systems B.V. Bestimmung von Protein-Bindungsstellen
CA2818654A1 (en) * 2000-10-20 2002-04-25 Como Biotech Aps Pregnancy-associated plasma protein-a2 (papp-a2)
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
US7521548B2 (en) 2001-02-07 2009-04-21 Burnham Institute For Medical Research Apoptosis modulator Bcl-B and methods for making and using same
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US20020160527A1 (en) 2001-02-26 2002-10-31 3M Innovative Properties Company Combinatorial library comprising pouches as packages for library members and method therefor
US6849449B2 (en) 2001-03-01 2005-02-01 Regents Of The University Of Michigan Orphanin FQ receptor nucleic acids
US7514263B2 (en) 2001-04-02 2009-04-07 3M Innovative Properties Company Continuous process for the production of combinatorial libraries of materials
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
CN100352501C (zh) * 2001-04-26 2007-12-05 比奥根艾迪克Ma公司 Cripto阻断抗体及其用途
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
ES2372321T3 (es) 2001-06-20 2012-01-18 Genentech, Inc. Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
AU2003904154A0 (en) 2003-08-07 2003-08-21 Bionomics Limited Mutations in ion channels
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CA2461372C (en) 2001-09-27 2014-01-07 Bionomics Limited Dna sequences for human angiogenesis genes
US7354898B2 (en) 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
EP1440083B1 (de) 2001-10-25 2013-01-02 Medical Research Council Moleküle
US20050080026A1 (en) 2001-10-29 2005-04-14 Arnd Steuernagel Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism
US7462472B2 (en) 2001-11-02 2008-12-09 The University Of Chicago Methods and compositions relating to anthrax pathogenesis
KR20070087247A (ko) 2002-01-02 2007-08-27 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
CA2472927A1 (en) 2002-01-10 2003-07-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel splice variant of myd88 and uses thereof
US6861523B2 (en) 2002-02-08 2005-03-01 Torrey Pines Institute For Molecular Studies 1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
WO2003070902A2 (en) 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003231740A1 (en) 2002-04-19 2003-11-03 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Compositions and methods for diagnostics and therapeutics for hydrocephalus
US20040171034A1 (en) * 2002-05-03 2004-09-02 Brian Agnew Compositions and methods for detection and isolation of phosphorylated molecules
US7102005B2 (en) * 2002-05-03 2006-09-05 Molecular Probes, Inc. Compositions and methods for detection and isolation of phosphorylated molecules
US7445894B2 (en) * 2002-05-03 2008-11-04 Molecular Probes, Inc. Compositions and methods for detection and isolation of phosphorylated molecules
EP1507553A2 (de) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pankreas spezifische proteine
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
CA2486252C (en) 2002-06-07 2012-07-24 Genentech, Inc. Methods for screening for agents that modulate hepatocellular carcinoma development
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2006512903A (ja) 2002-09-11 2006-04-20 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003276874B2 (en) 2002-09-11 2009-09-03 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP1539228B1 (de) 2002-09-11 2010-12-29 Genentech, Inc. Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
EP1556072B1 (de) 2002-09-17 2010-05-19 Antigen Express, Inc. Ii-key/antigene epitop-hybrid-peptid-vakzine
EP2500438A3 (de) 2002-09-25 2012-11-28 Genentech, Inc. Neue Zusammensetzungen und Verfahren zur Behandlung von Psoriasis
CN100572535C (zh) 2002-10-22 2009-12-23 卫材R&D管理有限公司 在分裂停止后的产多巴胺型神经元前体细胞中特异性表达的基因
EP2322203A3 (de) 2002-10-29 2011-07-27 Genentech, Inc. Gestaltungen und methoden für die behandlung von Immune verwandte Krankheiten
EP1581169A4 (de) 2002-11-08 2008-09-17 Genentech Inc Zusammensetzungen und verfahren zurbehandlung von erkrankungen in verbindung mit natürlichen killerzellen
EP1572116A4 (de) 2002-11-26 2007-12-12 Genentech Inc Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
AU2003299314A1 (en) 2002-12-16 2004-07-09 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
GB0300718D0 (en) 2003-01-13 2003-02-12 Ares Trading Sa Proteins
US7887752B2 (en) * 2003-01-21 2011-02-15 Illumina, Inc. Chemical reaction monitor
US6910785B2 (en) * 2003-01-22 2005-06-28 Cooper Technologies Company Industrial luminaire with prismatic refractor
EP1452868A2 (de) 2003-02-27 2004-09-01 Pepscan Systems B.V. Verfahren zur Selektion eines potenziellen Arzneimittels
US20040185499A1 (en) * 2003-03-20 2004-09-23 Jolley Michael E. Method of epitope scanning using fluorescence polarization
AU2003901425A0 (en) 2003-03-27 2003-04-10 Bionomics Limited A diagnostic method for epilepsy
AU2003901511A0 (en) 2003-03-28 2003-04-17 Bionomics Limited Nucleic acid molecules associated with angiogenesis II
CA2521940C (en) 2003-04-23 2010-01-26 Latrobe University Insect chymotrypsin and inhibitors thereof
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
US7173010B2 (en) 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
AU2003241006B2 (en) 2003-05-21 2011-03-24 Ares Trading S.A. TNF-like secreted protein
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
EP1644406B1 (de) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Verwendung von dg153 sekretierter proteinprodukte zur prevention und behandlung von pankreaserkrankungen und/oder fettleibigkeit und/oder metabolischem syndrom
US8501473B2 (en) 2003-07-16 2013-08-06 Evotec International Gmbh Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
AU2004203373A1 (en) 2003-07-25 2005-02-10 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
US20050095648A1 (en) * 2003-10-30 2005-05-05 Mario Geysen Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
MXPA06005219A (es) 2003-11-12 2007-01-19 Univ Colorado Regents Composiciones y metodos para la regulacion del factor-alfa de necrosis tumoral.
JP4901478B2 (ja) 2003-11-17 2012-03-21 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
EP1694352A2 (de) 2003-11-19 2006-08-30 DeveloGen Aktiengesellschaft Verwendung von sezernierten proteinprodukten zur prävention und behandlung von pankreaserkrankungen und/oder fettsucht und/oder des metabolischen syndroms
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
EP1729795B1 (de) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albuminfusionsproteine
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
WO2005079840A2 (en) 2004-02-20 2005-09-01 Develogen Aktiengesellschaft Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
DK1749029T3 (da) 2004-05-27 2011-06-06 Crucell Holland Bv Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
US20080199437A1 (en) 2004-07-22 2008-08-21 Eisai Co., Ltd. Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
WO2006031322A2 (en) 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
EP2298897B1 (de) 2004-09-02 2013-08-14 Yale University Regulierung von Onkogenen durch mikro-RNAs
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
CA2590180A1 (en) 2004-12-10 2006-06-15 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Binding partners of antibodies specific for dendritic cell antigens
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
PL1838350T3 (pl) 2005-01-20 2015-02-27 Ryboquin Company Ltd Modulatory aktywności ubikwitynazy itch
US7531523B2 (en) 2005-02-17 2009-05-12 Vertex Pharmaceuticals Incorporated Sodium channel protein type III alpha-subunit splice variant
EP1869076A2 (de) 2005-03-10 2007-12-26 Genentech, Inc. Verfahren und zusammensetzungen zur modulation der gefässintegrität
EP1863531A1 (de) 2005-03-19 2007-12-12 Medical Research Council Verbesserungen der behandlung und prävention von virusinfektionen
CA2601267C (en) 2005-03-24 2014-02-18 Thromb-X N.V. Novel anti-plgf antibody
US20060246576A1 (en) * 2005-04-06 2006-11-02 Affymetrix, Inc. Fluidic system and method for processing biological microarrays in personal instrumentation
EP1874331B1 (de) 2005-04-19 2014-09-03 Kings College London Verwendung von bip gegen knochenverlust und osteoporose
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2006132598A1 (en) 2005-06-07 2006-12-14 Temasek Life Sciences Laboratory Limited Porcine circovirus type 2 vaccines
US8354384B2 (en) 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
DK1910535T3 (en) 2005-06-24 2016-09-26 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH-3-like molecules and method of forming and / or selecting the same
EP1904095B1 (de) 2005-06-30 2013-05-29 VIB, vzw Behandlung von leberzirrhose und ihre komplikationen
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
CA2619736C (en) 2005-08-18 2012-05-22 Eisai R & D Management Co., Ltd. Dopaminergic neuron proliferative progenitor cell marker msx1/2
ES2400520T3 (es) 2005-09-29 2013-04-10 Eisai R&D Management Co., Ltd. Molécula de adhesión a las células T y anticuerpo contra la molécula
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
AU2006335053A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
EP1976567B1 (de) 2005-12-28 2020-05-13 The Scripps Research Institute Natürliche antisense- und nicht-kodierende rna-transkripte als arzneitargets
BRPI0706368A2 (pt) 2006-01-06 2011-03-22 Univ Georgia composição, vetor, método para fornecer resistência ao cisto nematódeo a uma planta, proteìna de fusão, método para inibir atividade biológica, ácido nucléico isolado
EP1973946B1 (de) 2006-01-20 2015-03-25 Cell Signaling Technology, Inc. Translokation und mutations-ros-kinase bei menschlichem nicht-kleinzelligem lungenkrebs
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
EP2002005A4 (de) 2006-03-17 2009-12-09 Univ Mcgill Identifizierung von crmp4 als konvergenzregulator der axonauswuchshemmung
EP2614839A3 (de) 2006-04-05 2015-01-28 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
CN101466836A (zh) 2006-04-11 2009-06-24 卫材R&D管理有限公司 多巴胺能神经元祖细胞标志物187a5
ES2637592T3 (es) 2006-04-14 2017-10-13 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
ES2530716T3 (es) 2006-04-21 2015-03-04 Intervet Int Bv Especies de pestivirus
US7723564B2 (en) 2006-05-10 2010-05-25 Board Of Regents Of The University Of Nebraska Compositions and methods for modulation of KSR1 and KSR2 interactions
US20080003667A1 (en) * 2006-05-19 2008-01-03 Affymetrix, Inc. Consumable elements for use with fluid processing and detection systems
CA2654502C (en) 2006-06-06 2015-07-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
EA031202B1 (ru) 2006-06-06 2018-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
CA2658952A1 (en) 2006-07-27 2008-01-31 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cellular receptor for antiproliferative factor
EP2434017A3 (de) 2006-08-01 2012-09-05 Board of Regents of the University of Texas System Identifizierung einer Mikro-RNA, die die Expression der Beta-Myosin-Schwerkette aktiviert
EP2520935A3 (de) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organspezifische Proteine und Verfahren zu deren Verwendung
ES2402217T3 (es) 2006-09-07 2013-04-29 Crucell Holland B.V. Moléculas de unión humanas que pueden neutralizar el virus influenza H5N1 y usos de las mismas
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
ATE522625T1 (de) 2006-09-12 2011-09-15 Genentech Inc Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
JPWO2008035527A1 (ja) * 2006-09-21 2010-01-28 隆弘 越智 抗Ｃ１ｑモノクローナル抗体
NZ590631A (en) 2006-09-21 2011-12-22 Probiodrug Ag Novel genes related to glutaminyl cyclase
EP2081596A4 (de) 2006-10-06 2010-07-21 Univ Utah Res Found Verfahren zum nachweis von augenkrankheiten und pathologischen zuständen und behandlung dafür
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
AU2007353396C1 (en) 2006-11-02 2013-06-27 Biomolecular Holdings Llc Hybrid immunoglobulins with moving parts
CA2669084A1 (en) 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Pak modulators
ES2777652T3 (es) 2006-12-21 2020-08-05 H Lundbeck As Modulación de la actividad de proneurotrofinas
EP2913341A1 (de) 2006-12-22 2015-09-02 University of Utah Research Foundation Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
JPWO2008111464A1 (ja) 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
US20100086931A1 (en) 2007-03-05 2010-04-08 Eisai R&D Management Co., Ltd. Method for assaying action of antitumor agent using decrease in gene expression level as index
AU2008269689A1 (en) 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
KR101554996B1 (ko) 2007-07-31 2015-09-23 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 섬유증을 조절하는 마이크로-ｒｎａ 집단 및 이의 용도
CA2700162C (en) 2007-09-25 2018-08-14 Pastoral Greenhouse Gas Research Ltd Cell-permeabilising peptides and polypeptides for microbial cells
US8309351B2 (en) 2007-10-04 2012-11-13 Bionomics Limited Methods of identifying agents that inhibit angiogenesis
AU2008314567B2 (en) 2007-10-18 2014-11-20 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
MX2010005108A (es) 2007-11-07 2010-05-27 Genentech Inc Composiciones y metodos para el tratamiento de trastornos microbianos.
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
US20110177502A1 (en) 2008-02-19 2011-07-21 Hakon Hakonarson Identification of pediatric onset inflammatory disease loci and methods of use thereof for the diagnosis and treatment of the same
GB0804702D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
CA2718520C (en) 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
EP2291544B1 (de) 2008-05-16 2017-10-25 The Children's Hospital of Philadelphia Genetische veränderungen auf chromosomen 21q, 6q und 15q sowie verfahren zur verwendung davon bei der diagnose und behandlung von typ-i-diabetes
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
CA2735710A1 (en) 2008-08-04 2010-02-11 Glen N. Barber Sting (stimulator of interferon genes), a regulator of innate immune responses
CA2736929C (en) 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
BRPI0921805A2 (pt) * 2008-11-03 2016-11-01 Alethia Biotherapeutics Inc anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor
CN102272157B (zh) 2008-11-07 2015-11-25 研究发展基金会 用于抑制cripto/grp78复合物形成和信号的组合物和方法
KR101829469B1 (ko) 2008-12-04 2018-03-30 큐알엔에이, 인크. Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
MX2011005912A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
EP3266795A1 (de) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Verfahren zum detektieren von fig-ros-fusionspolynukleotid
CA2752237C (en) 2009-02-12 2020-03-24 Opko Curna, Llc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
GB0903759D0 (en) 2009-03-04 2009-04-15 Medical Res Council Compound
US9464287B2 (en) 2009-03-16 2016-10-11 Curna, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
CA2754605C (en) 2009-03-19 2018-04-17 Medical Research Council Technology Pyrazolopyridine compounds and their use as lrrk2 inhibitors
KR101722541B1 (ko) 2009-05-06 2017-04-04 큐알엔에이, 인크. Ｔｔｐ에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
US9155754B2 (en) 2009-05-06 2015-10-13 Curna, Inc. Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
JP5931720B2 (ja) 2009-05-08 2016-06-08 クルナ・インコーポレーテッド Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
EP2432882B1 (de) 2009-05-22 2019-12-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
WO2010138806A2 (en) 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CN102612560B (zh) 2009-06-16 2017-10-17 库尔纳公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
EP2443459B1 (de) 2009-06-19 2018-12-26 The Arizona Board of Regents, A Body Corporate Of the State of Arizona acting for and on behalf Of Arizona State University Verbindungsanordnungen für probenprofil
JP6073133B2 (ja) 2009-06-24 2017-02-01 クルナ・インコーポレーテッド 腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療
WO2010151674A2 (en) 2009-06-26 2010-12-29 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
WO2011011700A2 (en) 2009-07-24 2011-01-27 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
ES2585360T3 (es) 2009-08-05 2016-10-05 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
ES2599986T3 (es) 2009-08-11 2017-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ)
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
KR101892760B1 (ko) 2009-08-25 2018-08-28 큐알엔에이, 인크. ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료
CA2772224C (en) 2009-08-27 2022-08-23 Pastoral Greenhouse Gas Research Ltd Complete genome sequence of the methanogen methanobrevibacter ruminantium
GB0915332D0 (en) 2009-09-02 2009-10-07 Univ Leuven Kath New methods for diagnosing autoimmune diseases
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
WO2011038210A2 (en) 2009-09-25 2011-03-31 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
US9366667B2 (en) 2009-10-02 2016-06-14 The Trustees Of Columbia University In The City Of New York Piscine reovirus diagnostic compositions
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
NZ600104A (en) 2009-11-09 2013-11-29 Genepod Therapeutics Ab Novel viral vector construct for neuron specific optimized continuous DOPA synthesis in vivo
SG10201408598XA (en) 2009-11-30 2015-02-27 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
RU2639550C2 (ru) 2009-12-16 2017-12-21 Курна, Инк. Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
WO2011079263A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011079261A2 (en) 2009-12-23 2011-06-30 Curna, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
ES2657452T3 (es) 2009-12-29 2018-03-05 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor respiratorio nuclear 1 (NRF1) mediante inhibición de transcrito antisentido natural a NRF1
DK2519632T3 (en) 2009-12-31 2018-07-23 Curna Inc TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2- (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPTION TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
WO2011082409A2 (en) 2010-01-04 2011-07-07 Curna, Inc. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
ES2664866T3 (es) 2010-01-11 2018-04-23 Curna, Inc. Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
WO2011091390A2 (en) 2010-01-25 2011-07-28 Opko Curna, Llc Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
GB201002911D0 (en) 2010-02-19 2010-04-07 Medical Res Council Compound
US8962586B2 (en) 2010-02-22 2015-02-24 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
GB201004850D0 (en) 2010-03-23 2010-05-05 Natural Environment Res Council Proteins
TWI600759B (zh) 2010-04-02 2017-10-01 可娜公司 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病
EP2374816B1 (de) 2010-04-07 2016-09-28 Agency For Science, Technology And Research Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
JP5978203B2 (ja) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
PE20130460A1 (es) 2010-05-03 2013-04-26 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
RU2018110642A (ru) 2010-05-03 2019-02-27 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
NO2576784T3 (de) 2010-05-26 2018-04-14
EP3299464B1 (de) 2010-05-26 2019-10-02 CuRNA, Inc. Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
JP6023705B2 (ja) 2010-06-23 2016-11-09 カッパーアールエヌエー，インコーポレイテッド ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
CN103068982B (zh) 2010-07-14 2017-06-09 库尔纳公司 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
EP2625274B1 (de) 2010-10-06 2017-07-19 CuRNA, Inc. Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
WO2012051306A2 (en) 2010-10-12 2012-04-19 Gencia Corporation Compositions and methods for modulating mitochondrial proteases
JP6049623B2 (ja) 2010-10-22 2016-12-21 カッパーアールエヌエー，インコーポレイテッド α‐Ｌ‐イズロニダーゼ（ＩＤＵＡ）への天然アンチセンス転写物の阻害によるＩＤＵＡ関連疾患の治療
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
JP5980810B2 (ja) 2010-12-29 2016-09-07 インターベット インターナショナル ベー． フェー． イヌバベシア症ワクチン抗原
GB201104669D0 (en) 2011-03-18 2011-05-04 Medical Res Council Technology Compound
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
US9139824B2 (en) 2011-04-21 2015-09-22 The University Court Of The University Of Aberdeen Sapolegina protein in for use as a medicament
WO2012162514A2 (en) 2011-05-26 2012-11-29 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
ES2653247T3 (es) 2011-06-09 2018-02-06 Curna, Inc. Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN
MX346206B (es) 2011-07-14 2017-03-09 Crucell Holland Bv Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
EA026924B1 (ru) 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
EA029151B1 (ru) 2011-09-06 2018-02-28 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
AU2012306282A1 (en) 2011-09-08 2014-03-20 Umc Utrecht Holding B.V. Vaccine based on Staphylococcal superantigen-like 3 protein (SSL3)
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
JP2014533927A (ja) 2011-09-15 2014-12-18 ジェネンテック， インコーポレイテッド 分化を促進する方法
PL2760463T3 (pl) 2011-09-20 2019-05-31 Univ North Carolina Chapel Hill Regulacja kanałów sodowych przez białka PLUNC
US9678062B2 (en) 2011-09-23 2017-06-13 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
JP6532678B2 (ja) 2011-10-14 2019-06-19 ジェネンテック， インコーポレイテッド 抗ＨｔｒＡ１抗体及び使用方法
EP2766000A2 (de) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1-antagonisten zur behandlung von krebs
PL396675A1 (pl) 2011-10-17 2013-04-29 Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Pan Gen Grainyhead-like 1 i czynnik transkrypcyjny Grainyhead-like 1 do zastosowania w regulowaniu cisnienia krwi u ssaków
WO2013059884A1 (en) 2011-10-28 2013-05-02 Itek Ventures Pty Ltd A gene and mutations thereof associated with seizure and movement disorders
JP2015501639A (ja) 2011-11-23 2015-01-19 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗ｃｄ９８抗体およびその使用方法
AU2012321082B2 (en) 2011-12-01 2015-03-12 Oxurion NV Improving trabeculectomy outcome
JP2015506944A (ja) 2012-01-18 2015-03-05 ジェネンテック， インコーポレイテッド Ｆｇｆ１９修飾薬を使用する方法
WO2013113865A1 (en) 2012-02-03 2013-08-08 The Pirbright Institute Eimeria vector vaccine for campylobacter jejuni
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
JP6253596B2 (ja) 2012-02-16 2017-12-27 ザ ペン ステイト リサーチ ファンデーション アシル補酵素ａ：リゾカルジオリピン・アシル基転移酵素１（ａｌｃａｔ１）の発現、機能または活性の阻害物質を同定する方法
WO2013132007A1 (en) 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
TR201815503T4 (tr) 2012-03-15 2018-11-21 Curna Inc Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
EP2825549B1 (de) 2012-03-16 2018-10-10 F. Hoffmann-La Roche SA Gleichmässig stabilisierte manipulierte proteine
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
CN106290917B (zh) 2012-04-25 2020-06-05 比奥德赛公司 用于检测蛋白质的变构调节剂的方法
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
SG11201407859YA (en) 2012-05-31 2014-12-30 Genentech Inc Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9512201B2 (en) 2012-09-27 2016-12-06 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20160228528A1 (en) 2013-01-28 2016-08-11 Janssen Sciences Ireland Uc A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
JP2016516046A (ja) 2013-03-14 2016-06-02 ジェネンテック， インコーポレイテッド がんの治療方法及びがん薬物耐性を阻止する方法
EP3385277A1 (de) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22-polypeptide und il-22-fc-fusionsproteine sowie verfahren zur verwendung
KR20230070054A (ko) 2013-03-15 2023-05-19 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
US10208290B2 (en) 2013-06-21 2019-02-19 The Johns Hopkins University Virion display array for profiling functions and interactions of human membrane proteins
WO2015009856A2 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
CN105899535A (zh) 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
US9738716B2 (en) 2014-01-24 2017-08-22 Ngm Biopharmaceuticals, Inc. Beta klotho binding proteins and methods of use thereof
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
EP3137482A1 (de) 2014-05-02 2017-03-08 MorphoSys AG Peptidbibliotheken
RU2020103811A (ru) 2014-05-05 2020-02-18 Регенерон Фармасьютикалз, Инк. Гуманизированные животные по с5 и с3
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
DK3164123T3 (da) 2014-07-02 2020-08-03 Inflectis Bioscience Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
PL3164391T3 (pl) 2014-07-02 2019-12-31 Inflectis Bioscience Pochodne O-alkilo-benzylidenoguanidyny i zastosowanie terapeutyczne w leczeniu zaburzeń związanych z akumulacją nieprawidłowo pofałdowanych białek
AR101210A1 (es) 2014-07-15 2016-11-30 Genentech Inc Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
EP3188746B1 (de) 2014-09-05 2024-06-19 The Johns Hopkins University Capn9-aktivität als ziel für eine therapeutische strategie zur behandlung von myofibroblastendifferenzierung und assoziierten erkrankungen
US10704098B2 (en) 2014-10-29 2020-07-07 The Children's Hospital Of Philadelphia Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
PL3221355T3 (pl) 2014-11-20 2021-03-08 F. Hoffmann-La Roche Ag Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1
US20160158360A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
CA2975655C (en) 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
EP3253787B1 (de) 2015-02-05 2020-10-07 Janssen Vaccines & Prevention B.V. Humane neutralisierende antikörper gegen influenza-neuraminidase
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CN114907271B (zh) 2015-05-22 2024-05-07 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
US20180188257A1 (en) 2015-06-19 2018-07-05 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
AU2016313506A1 (en) 2015-08-21 2018-03-08 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
WO2017058780A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
ES2870141T3 (es) 2015-10-30 2021-10-26 Hoffmann La Roche Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
EP3371211A4 (de) 2015-11-04 2019-08-21 Icahn School of Medicine at Mount Sinai Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
CA3048204A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response
EP3423484B1 (de) 2016-03-01 2021-01-13 Janssen Vaccines & Prevention B.V. Humane neutralisierende antikörper gegen influenza-b-neuraminidase
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
JP6797219B2 (ja) 2016-06-15 2020-12-09 スーチョウ ヤバオ ファーマスーティカル アールアンドディー カンパニー リミテッド 置換三環式複素環化合物及びその用途
JP2019528428A (ja) 2016-06-20 2019-10-10 ヘルステル・インコーポレイテッドＨｅａｌｔｈｔｅｌｌ Ｉｎｃ． 自己免疫疾患の鑑別診断方法
WO2017223117A1 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
EP3481835A4 (de) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. Calpain-modulatoren und therapeutische verwendungen davon
CN110023304A (zh) 2016-09-28 2019-07-16 布莱德治疗公司 钙蛋白酶调节剂及其治疗用途
WO2018089858A1 (en) 2016-11-11 2018-05-17 Healthtell Inc. Methods for identifying candidate biomarkers
WO2018098401A1 (en) 2016-11-23 2018-05-31 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
GB201622362D0 (en) 2016-12-29 2017-02-15 Medical Res Council Tech Compounds
GB201622365D0 (en) 2016-12-29 2017-02-15 Medical Res Council Tech Compounds
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
SG11201907606XA (en) 2017-02-27 2019-09-27 Regeneron Pharma Humanized model of kidney and liver disorders
WO2018170464A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Targeted epigenetic therapy against distal regulatory element of tgfb2 expression
JP7248588B2 (ja) 2017-04-21 2023-03-29 ジェネンテック， インコーポレイテッド 疾患の治療のためのｋｌｋ５アンタゴニストの使用
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3641752A4 (de) 2017-06-22 2021-03-17 Moonshot Pharma LLC Verfahren zur behandlung von krebs mit zusammensetzungen mit amlexanox und immunmodulatoren
NZ760841A (en) 2017-07-11 2024-02-23 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11827669B2 (en) 2017-07-19 2023-11-28 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
WO2019046791A1 (en) 2017-09-01 2019-03-07 The Johns Hopkins University TARGETED EPIGENETIC THERAPY FOR AERIAL CONDITION OF AERTICAL HERITATION
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
CA3119161A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US20220111047A1 (en) 2019-01-16 2022-04-14 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
EP3917571A4 (de) 2019-01-31 2022-10-12 Agency For Science, Technology And Research Cnx/erp57-inhibitor zur verwendung bei der behandlung oder prävention von krebs
EP3976090A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
US20220378900A1 (en) 2019-11-20 2022-12-01 Intervet Inc. A novel vaccine against heamophilus parasuis
WO2021099446A1 (en) 2019-11-20 2021-05-27 Intervet International B.V. A novel vaccine against heamophilus parasuis
JP2023503057A (ja) 2019-11-20 2023-01-26 インターベット インターナショナル ベー． フェー． ヘモフィルス・パラスイスに対する新規ワクチン
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
KR20230091150A (ko) 2020-10-29 2023-06-22 수저우 야바오 파마슈티걸 알앤디 컴퍼니 리미티드 치환된 디아릴아민 화합물 및 이의 약학적 조성물, 제조 방법과 용도
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2023028501A1 (en) 2021-08-23 2023-03-02 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56115727A (en) * 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
FI83662C (fi) * 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
ZA831854B (en) * 1982-03-26 1984-01-25 Biogen Nv Small peptides with the specificity of foot and mouth disease viral antigens
US4438208A (en) * 1982-05-27 1984-03-20 The Regents Of The University Of California Region-specific determinants for vitamin K dependent bone protein
US4544629A (en) * 1982-11-19 1985-10-01 Minnesota Mining And Manufacturing Company Receptor-based histamine assay
US4504586A (en) * 1983-02-03 1985-03-12 Amgen Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1
US4708871A (en) * 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1984003506A1 (en) * 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences

Also Published As

Publication number Publication date
EP0138855A1 (de) 1985-05-02
DK164529C (da) 1992-11-23
EP0138855B2 (de) 1999-09-08
CA1220420A (en) 1987-04-14
NO844296L (no) 1984-10-29
ATE69890T1 (de) 1991-12-15
WO1984003564A1 (en) 1984-09-13
NO166466B (no) 1991-04-15
EP0138855B1 (de) 1991-11-27
DK532284D0 (da) 1984-11-08
JPS60500684A (ja) 1985-05-09
NZ207394A (en) 1987-03-06
EP0138855A4 (de) 1986-02-10
NO166466C (no) 1991-07-24
JPH063445B2 (ja) 1994-01-12
DK532284A (da) 1984-11-08
US5595915A (en) 1997-01-21
DK164529B (da) 1992-07-06

Similar Documents

Publication Publication Date Title
DE3485299D1 (de) Nachweis von antigen aktiven aminosaeurensequenzen.
NL300118I1 (nl) Voor Factor VIIIC coderende DNA-sequenties en verwante DNA-constructen.
KR850006548A (ko) 프리(pre)-S 유전자 코우드로 된 펩티드 B형 간염 면역원, 왁찐, 진단법 및 합성지질소낭 담체
ES8801839A1 (es) Procedimiento para detectar anticuerpos a htlv-iii y diagnosticar aids, arc o estados pre-aids
DE3789873D1 (de) Immunaffinitäts-reinigungssystem.
HU9202645D0 (en) Synthetic antigenes applicables for detecting antibodies of hepatitis c virus
DE58905081D1 (de) Verfahren zur bestimmung eines proteins nach dem prinzip des fluoreszenz-polarisations immunoassays.
KR950008537A (ko) 엡스타인 바 비루스(ebv)에 대한 항체의 검출용 진단제
NO913037L (no) Peptider med for alfal-mikroglobulin karakteristiske antigene determinanter.
KR940005666A (ko) C형 간염 바이러스를 분류하기 위한 항원성 펩티드 ,이 펩티드를 포함하는 키트 및 이 펩티드를 사용하여 c형 간염 바이러스를 분류하는 방법
NO942539D0 (no) Caseinmakropeptid, antistoffer rettet mot nevnte peptider og anvendelser derav
KR930004328A (ko) 비-a, 비-b형 펩티드
EP0443880A3 (en) Assay for equine infectious anemia virus
ES2060927T3 (es) Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.
NO910479L (no) Syntetiske polypeptider og antistoffer relatert til epstein-barr-virus-kjerneantigen.
KR960014341A (ko) 톡소플라즈마 곤디의 항원
ATE201697T1 (de) Antigenen peptide mit glycinsubstitution
NO982227D0 (no) Urogenitalcarcinom-TPL komplekspeptider og antistoffer derav
KR930007970A (ko) 비-에이 형 , 비-비형 펩티드
DE3853315D1 (de) Verfahren zur quantitativen Bestimmung von Serumproteinen in Körperflüssigkeiten und Mittel zur Durchführung des Verfahrens.
RU97109301A (ru) Способ обнаружения антител к ядерному белку вируса гепатита c
HUP9900766A2 (hu) Helicobacter pylorival kapcsolatos nukleinsav- és aminosavszekvenciák diagnosztikumokhoz és gyógyszerekhez
Szpirer Comparison of the cysteine-containing peptides from rabbit anti-tobacco mosaic virus antibody and non-specific immunoglobulin G by peptide mapping
KR900004763A (ko) Hiv-항체와 면역 화학적으로 반응하는 합성 폴리 펩티드
DE3485972D1 (de) Antigen aktive aminosaeuresequenzen.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON MIMOTOPES PTY. LTD., CLAYTON, VICTORIA, AU